Pharmacogenetics in drug development

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 360, Issue 1460, 2005, Pages 1579-1588

  McCarthy, Alun D ^a   Kennedy, James L ^b   Middleton, Lefkos T ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Diagnosis; Drug development; Drug discovery; Drug response; Pharmacogenetics; Pharmacogenomics

Indexed keywords

DISEASE; DRUG DEVELOPMENT; GENETICS; PHARMACEUTICAL INDUSTRY; PHENOTYPE;

ENGLAND; EURASIA; EUROPE; LONDON [ENGLAND]; UNITED KINGDOM; WESTERN EUROPE;

CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG DESIGN; GENETIC POLYMORPHISM; HUMAN; METHODOLOGY; PHARMACOGENETICS; PHARMACOKINETICS; REVIEW;

CLINICAL TRIALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; PHARMACOGENETICS; PHARMACOKINETICS; POLYMORPHISM, GENETIC;

EID: 33644690402     PISSN: 09628436     EISSN: None     Source Type: Journal    
DOI: 10.1098/rstb.2005.1688     Document Type: Conference Paper

References (53)

1. Basile, V. S., Masellis, M., Badri, F. et al. 1999 Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology 21, 17-27.
2. Campbell, C. J. & Ghazal, P. 2004 Molecular signatures for diagnosis of infection: application of microarray technology. J. Appl. Microbiol. 96, 18-23.
3. Chon, H. et al. 2004 Broadly altered gene expression in blood leukocytes in essential hypertension is absent during treatment. Hypertension 43, 947-951.
4. Chung, W. H., Hung, S. I., Hong, H. S., Hsih, M. S., Yang, L. C., Ho, H. C., Wu, J. Y. & Chen, Y. T. 2004 Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428, 486.
5. Cockcroft, J. R., Gazis, A. G., Cross, D. J., Wheatley, A., Dewar, J., Hall, I. P. & Noon, J. P. 2000 Beta(2)-adrenoceptor polymorphism determines vascular reactivity in humans. Hypertension 36, 371-375.
6. Daly, A. K. 2003 Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam. Clin. Pharmacol. 17, 27-41.
7. Danoff, T. M. et al. 2004 A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia. Pharmacogenomics J. 4, 49-53.
8. Debouck, C. & Metcalf, B. 2000 The impact of genomics on drug discovery. Annu. Rev. Pharmacol. Toxicol. 40, 193-207.
9. DeFife, K. M. & Wong-Staal, F. 2002 Integrated approaches to therapeutic target gene discovery. Curr. Opin. Drug Discov. Dev. 5, 683-689.
10. Devlin, B. & Roeder, K. 1999 Genomic control for association studies. Biometrics 55, 997-1004.
11. DiMasi, J., Hansen, R. W. & Grabowski, H. G. 2003 The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151-185.
12. Dishy, V., Sofowora, G. G., Xie, H. G., Kim, R. B., Byrne, D. W., Stein, C. M. & Wood, A. J. 2001 The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N. Engl. J. Med. 345, 1030-1035.
13. Dos Santos, C. et al. 2004 A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nature Genet. 36, 720-724.
14. Drazen, J. M. et al. 2003 Pharmacogenetic association between ALOEX5 promoter genotype and the response to anti-asthma treatment. Nature Genet. 22, 168-170.
15. Gilbert, J. 2003 Rebuilding big PhRMA's business model. In vivo, 73-80.
16. Goldstein, D. B., Tate, S. K. & Sisodiya, S. M. 2003 Pharmacogenetics goes genomic. Nature Rev. Genet. 4, 937-947.
17. Guzey, C., Norstrom, A. & Spigset, O. 2002 Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion. Ther. Drug Monit. 24, 436-437.
18. Hariri, A. R. & Weinberger, D. R. 2003 Functional neuroimaging of genetic variation in serotonergic neurotransmission. Genes Brain Behav. 2, 341-349.
19. Hetherington, S. et al. 2002 Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359, 1121-1122.
20. Ingelman-Sundberg, M. 2004 Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn-Schmiedebergs Arch. Pharmacol. 369, 89-104.
21. Israel, E. et al. 2001 National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Effect of polymorphism of the beta(2)-adrenergic receptor on response to regular use of albuterol in asthma. Int. Arch. Allergy Immunol. 124, 183-186.
22. Jacobsen, P., Rossing, K., Rossing, P., Tarnow, L., Mallet, C., Poirier, O., Cambien, F. & Parving, H. H. 1998 Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int. 53, 1002-1006.
23. Kohno, M., Yokokawa, K., Minami, M., Kano, H., Yasunari, K., Hanehira, T. & Yoshikawa, J. 1999 Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors. Am. J. Med. 106, 544-549.
24. Lazarou, J., Pomeranz, B. H. & Corey, P. N. 1998 Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. J. Am. Med. Assoc. 279, 1200-1205.
25. Lerer, B. et al. 2002 Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients support association with dopamine D3 receptor gene Ser9Gly polymorphism (a multi-center study). Neuropsychopharmacology 27, 105-119.
26. Lesko, L. J. & Woodcock, J. 2004 Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nature Rev. Drug Discov. 3, 763-769.
27. Lesko, L. J. et al. 2003 Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe Workshop. J. Clin. Pharmacol. 43, 342-358.
28. Lima, J. J., Thomason, D. B., Mohamed, M. H., Eberle, L. V., Self, T. H. & Johnson, J. A. 1999 Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin. Pharmacol. Ther. 65, 519-525.
29. Lin, K. M., Poland, R. E., Wan, Y. Y., Smith, M. & Lesser, I. M. 1996 The evolving science of pharmacogenetics: clinical and ethnic perspectives. Psychopharmacol. Bull. 32, 205-217.
30. Lin, K. M., Smith, M. W. & Ortiz, V. 2001 Culture and psychopharmacology. Psychiatr. Clin. North Am. 24, 523-537.
31. Lynch, T. J. et al. 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139.
32. Martinez, F. D., Graves, P. E., Baldini, M., Solomon, S. & Erickson, R. 1997 Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. Clin. Invest. 100, 3184-3188.
33. Mundo, E., Walker, M., Cate, T., Macciardi, F. & Kennedy, J. L. 2001 The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder. Arch. Gen. Psychiatry 58, 539-544.
34. Murphy, D. L., Lerner, A., Rudnick, G. & Lesch, K. P. 2004 Serotonin transporter: gene, genetic disorders, and pharmacogenetics. Mol. Interv. 4, 109-123.
35. Noble, M. E., Endicott, J. A. & Johnson, L. N. 2004 Protein kinase inhibitors: insights into drug design from structure. Science 303, 1800-1805.
36. Ohmichi, N., Iwai, N., Uchida, Y., Shichiri, G., Nakamura, Y. & Kinoshita, M. 1997 Relationship between the response to the angiotensin converting enzyme inhibitor imidapril and the angiotensin converting enzyme genotype. Am. J. Hypertens. 10, 951-955.
37. Okamura, A. et al. 1999 Pharmacogenetic analysis of the effect of angiotensin-converting enzyme inhibitor on restenosis after percutaneous transluminal coronary angioplasty. Angiology 50, 811-822.
38. Penno, G., Chaturvedi, N., Talmud, P. J., Cotroneo, P., Manto, A., Nannipieri, M., Luong, L. A. & Fuller, J. H. 1998 Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURO-DIAB Controlled Trial of Lisinopril in IDDM. Diabetes 47, 1507-1511.
39. Plumb, R. S., Stumpf, C. L., Granger, J. H., Castro-Perez, J., Haselden, J. N. & Dear, G. J. 2003 Use of liquid chromatography/time-of-flight mass spectrometry and multivariate statistical analysis shows promise for the detection of drug metabolites in biological fluids. Rapid Commun. Mass Spectrom. 17, 2632-2638.
40. Pritchard, J. K. & Rosenberg, N. A. 1999 Use of unlinked genetic markers to detect population stratification in association studies. Am. J. Hum. Genet. 65, 220-228.
41. Rau, T., Wohlleben, G., Wuttke, H., Thuerauf, N., Lunkenheimer, J., Lanczik, M. & Eschenhagen, T. 2004 CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants - a pilot study. Clin. Pharmacol. Ther. 75, 386-393.
42. Roses, A. D. 2002 Genome-based pharmacogenetics and the pharmaceutical industry. Nature Rev. Drug Discov. 1, 541-554.
43. Roses, A. D. 2004 Pharmacogenetics and drug development: the path to safer and more effective drugs. Nature Rev. Drug Discov. 3, 645-656.
44. Roses, A. D., Burns, D. K., Chissoe, S., Middleton, L. & St Jean, P. 2005 Disease-specific target selection: a critical first step down the right road. Drug Discov. Today 10, 177-189.
45. Searls, D. B. 2003 Pharmacophylogenomics: genes, evolution & drug targets. Nature Rev. Drug Discov. 2, 613-623.
46. Smeraldi, E., Zanardi, R., Benedetti, F., De Bella, D., Perez, J. & Catalano, M. 1998 Polymorphism within the promoter of the serotonin transporter gene and anti-depressant efficacy of fluvoxamine. Mol. Psychiatry 3, 508-511.
47. Steen, V. M., Lovlie, R., MacEwan, T. & McCreadie, R. G. 1997 Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol. Psychiatry 2, 139-145.
48. Subramanian, G., Adams, M. D., Ventnre, J. C. & Broder, S. 2001 Implications of the human genome for understanding human biology and medicine. J. Am. Med. Assoc. 286, 2296-2307.
49. Tantisira, K. G. et al. 2004 Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum. Mol. Genet. 13, 1353-1359.
50. Vogel, F. 1959 Moderne probleme der Humangenetik. Ergeb. Inn. Med. Kinderheilkd. 12, 52-125.
51. Vogel, C. L. & Franco, S. X. 2003 Clinical experience with trastuzumab (herceptin). Breast J. 9, 452-462.
52. Weatherall, D. J. 2001 Towards molecular medicine; reminiscences of the haemoglobin field, 1960-2000. Br. J. Haematol. 115, 729-738.
53. Yamanouchi, Y., Iwata, N., Suzuki, T., Kitajima, T., Ikeda, M. & Ozaki, N. 2003 Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. Pharmacogenomics J. 3, 356-361.